The University of Texas Health Science Center at Houston (UTHealth) has begun enrollment for the first Phase I safety study approved by the Food and Drug Administration to investigate the use of a child’s own umbilical cord blood stem cells for traumatic brain injury in children. The study is being performed in conjunction with Children’s Memorial Hermann Hospital, UTHealth’s primary children’s teaching hospital.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cordblood/48021/
Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif !
Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien.
To view the multimedia release go to:
http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
Volvo Cars today declares an end to a problem faced daily by drivers around the globe: a lack of suitable and functional storage space inside their car. With its innovative approach inside the new XC40 small city SUV, set to be launched in the coming weeks, Volvo Cars takes the lead in the small premium SUV segment in terms of space, storage and all-round functionality.
The highly anticipated XC40 from Volvo Cars will complete the company’s SUV line-up that also features the top-of-the-range large XC90 and the mid-sized XC60.
As part of the XC40’s development phase, Volvo Cars’ customer research team spent considerable time investigating how city dwellers around the globe use their car on a daily basis – and, more importantly, how they store their belongings in their cars. Customers were also asked how they would like to see the interiors of their cars improved.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8163951-end-clutter-volvo-cars-XC40-small-SUV/
The latest phase of Tourism Australia’s global marketing campaign, There’s nothing like Australia, has been launched today in China – Australia’s fastest growing and most valuable overseas tourism market.
In addition to a new broadcast ad and print executions the campaign boasts a strong digital and social media focus, and will leverage the advocacy of Tourism Australia’s three million Facebook fans. Other elements include a new, interactive tablet app and hub on www.australia.com, to take customers further into the stories played out in the ad and provide more information on the locations.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56340-tourism-australia-global-marketing-campaign-there-s-nothing-like-australia
Saxo Bank, the online trading and investment specialist, today releases their Q3 outlook that views Europe as insolvent, in a phase of denial of the actual problems and without a credible path forward. The Bank’s analysts also predict that growth in China will decrease to 6.5 percent, marking the next quarter as the low point for China and for world growth in general.
For the current crisis, Saxo Bank operates with a three-phase model that includes; Denial (which prompts policy-makers and central bankers to rely on quantitative easing and financial stimulus); Protest (where the public votes new governments which still fail to address the real problems) and; Mandate for Change (which forces policy-makers to take real action). According to the Bank, the EU has remained embedded in the first and second phases, having yet to arrive at a mandate for change.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/saxobank/56575/
Sands China’s Cotai Strip® development was beautifully aflame in celebration Thursday evening, as the integrated resort city introduced to Macao the latest additions at Sands® Cotai Central, led by the launch of Sheraton Macao Hotel, Cotai Central, which has the double distinction of being the largest hotel for both Macao and Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58010-sands-cotai-central-celebrates-second-phase-opening
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
National Instruments (Nasdaq: NATI) today introduced a 14 GHz version of its NI PXIe-5665 high-performance RF vector signal analyzer (VSA), which delivers best-in-class dynamic range and accuracy in a cost-effective PXI form factor. The new VSA features industry-leading phase noise and dynamic range, regardless of form factor, including traditional rack-and-stack instruments. Because of its PXI platform, the VSA can deliver measurement speeds up to 20 times faster than box instruments and for less cost. Additionally, it takes advantage of multicore computing architectures and parallel programming capabilities through NI LabVIEW system design software. It also offers peer-to-peer data streaming for signal processing and a flexible multiple input, multiple output (MIMO) architecture for phase-coherent measurements. Such features make it ideal for demanding RF test applications including radio detection and ranging (RADAR), satellite, radio and harmonic testing.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nationalinstruments/51200/
